Table 3. Kaplan-Meier analysis on patient's CCSS.

Prognostic variable	Grouping factor	Mean (months)	SE (months)	95% CI (lower-upper)	X2	p
Sex	Male	69.670	3.319	63.164–76.175	6.278	0.012
	Female	54.911	5.216	44.689–65.134
T stage	T2–T3	74.363	3.495	67.513–81.214	8.215	0.004
	T4a–T4b	56.711	4.061	48.751–64.670
N stage	N0	77.898	2.392	73.209–82.588	22.908	0.000
	N1–N2	48.913	4.950	39.211–58.614
M stage	M0	79.188	1.905	75.455–82.922	107.858	0.000
	M1	19.610	4.043	11.685–27.535
AJCC TNM Stage	I–II	81.395	1.758	77.949–84.841	30.134	0.000
	III–IV	48.409	4.624	39.347–57.472
LMR Level	Low	57.414	4.679	48.243–66.585	5.582	0.018
	High	69.692	3.376	63.076–76.309
MSI Status	MSI–L/MSS	60.766	3.317	54.264–67.267	6.380	0.012
	MSI–H	81.895	3.022	75.971–87.819
18q LOH	No	72.341	3.900	64.696–79.986	4.258	0.039
	Yes	59.258	3.968	51.482–67.035
Serum CEA level	Normal	70.678	3.304	64.202–77.154	7.606	0.006
	Elevated	55.259	5.117	45.231–65.288
Serum CA199 level	Normal	75.834	2.587	70.762–80.905	37.850	0.000
	Elevated	38.593	5.144	28.511–48.674
LVI	No	71.556	3.060	65.558–77.554	10.980	0.001
	Yes	50.982	5.675	39.859–62.105
PNI	No	68.083	2.934	62.332–73.834	7.805	0.005
	Yes	45.389	8.922	27.903–62.875
ENTD	No	69.139	2.882	63.490–74.788	16.714	0.000
	Yes	33.748	6.840	20.341–47.154

*Log Rank (Mantel-Cox) test was used to test the significance of the different survival between the groups according to different variables. A two-tailed p value ≤0.05 was considered statistically significant.

Abbreviations: CCSS, colon cancer specific survival; SE, standard error; CI, confidence interval; AJCC, American Joint Committee on Cancer (AJCC); LMR, LINE-1 methylation rate; 18q LOH, loss of heterozygosity at chromosome 18q; MSI, micro-satellite instable; MSS, micro-satellite stable; CEA, carcinoembryonic antigen; CA199, Carbohydrate antigen 199; LVI, lymphovascular invasion; PNI, perineural invasion; ENTD, extranodal tumor deposits.